Johnson & Johnson bought the front door to every left-sided ablation procedure. On April 24, J&J announced the acquisition of Atraverse Medical and its HOTWIRE™ transseptal access system — the radiofrequency guidewire that creates controlled passage across the interatrial septum for cardiac ablation, mitral valve interventions, and left atrial appendage closure. Roughly 3,000 clinical procedures in, the technology now belongs to Biosense Webster, J&J’s electrophysiology platform. The day before, FDA and CMS jointly launched the RAPID Coverage Pathway — a framework that compresses Medicare reimbursement timelines from 9–12 months to 60–90 days for breakthrough-designated devices. Approximately 40 devices are immediately eligible. And before the week was out, Boston Scientific and Edwards Lifesciences both beat Q1 estimates — BSX posting $5.2B in revenue on FARAPULSE strength, and Edwards raising its full-year outlook after TAVR revenue grew 14.4% year-over-year. Welcome to Issue #17 of The MedTech Minute — the week access got faster.
Top Stories
Story 01
Johnson & Johnson announced on April 24 the acquisition of Atraverse Medical and its HOTWIRE™ Transseptal Access System, a radiofrequency guidewire-and-generator combination used to create controlled access across the interatrial septum during cardiac ablation procedures. The deal is expected to close in Q2 2026. Financial terms were not disclosed. Atraverse had been gaining commercial momentum since Biosense Webster showcased clinical procedure data at the Stanford Biodesign Retreat on April 22 — two days before the acquisition announcement confirmed what the clinical buzz had been signaling.
The HOTWIRE system had been used in approximately 3,000 clinical procedures at the time of the acquisition. Transseptal access is the procedural gateway for left-sided cardiac ablation — atrial fibrillation ablation, mitral valve interventions, left atrial appendage closure. The quality and consistency of the transseptal crossing directly affects every downstream step. HOTWIRE uses radiofrequency energy to create a controlled, precise puncture rather than relying on mechanical pressure, reducing procedural variability and the risk of inadvertent cardiac perforation. (Source: Surgical Robotics Technology, April 24, 2026)
Why It Matters: J&J’s Biosense Webster is the dominant force in cardiac electrophysiology — the CARTO mapping platform and THERMOCOOL catheters define the workflow for most EP labs globally. Adding HOTWIRE gives Biosense Webster a proprietary transseptal access solution to lead with before competitors do. The acquisition is small in dollars but strategically precise: every ablation procedure that starts with HOTWIRE is a procedure that starts inside the Biosense Webster ecosystem.
Acquisition
Cardiac Ablation
Biosense Webster
Why This Matters for Builders
The Atraverse acquisition is a textbook example of ecosystem strategy in medtech. J&J didn’t buy HOTWIRE because transseptal access is a standalone revenue opportunity — they bought it because every ablation that starts with HOTWIRE starts inside the Biosense Webster workflow. For founders building devices that touch a procedural workflow owned by a large platform player, the lesson is clear: your device’s strategic value isn’t just what it does — it’s whose ecosystem it completes. Build a technology that becomes the natural first step in a dominant procedural platform, and the acquisition conversation writes itself.
Story 02
The FDA and the Centers for Medicare & Medicaid Services jointly announced the RAPID Coverage Pathway on April 23, a new framework that fundamentally compresses the timeline between FDA device approval and Medicare reimbursement. Under the existing system, breakthrough-designated devices approved by the FDA typically wait 9–12 months — and sometimes far longer — before CMS issues reimbursement coverage determinations. The RAPID pathway changes that: CMS will issue a proposed National Coverage Determination concurrent with or immediately following FDA approval for eligible breakthrough-designated devices, targeting final coverage within 60–90 days.
Approximately 40 currently approved breakthrough devices are immediately eligible for expedited coverage review. For future approvals, the synchronized FDA-CMS workflow means that commercial launch no longer stalls at the reimbursement gate. The reimbursement gap has been one of the most persistent criticisms of the U.S. device regulatory framework — companies invest in clinical trials to win FDA clearance, then spend another year navigating a parallel federal bureaucracy before hospitals can get paid for using the approved device. The RAPID pathway collapses that sequential process into a coordinated one. (Source: CMS/FDA joint announcement, April 23, 2026)
Why It Matters: The companies with the most to gain are those with large breakthrough device portfolios already on the market: Medtronic, J&J MedTech, and Boston Scientific, which has been aggressively accumulating breakthrough designations across its structural heart and electrophysiology franchises. For smaller companies, the pathway removes the “approval purgatory” risk that has historically made MedTech venture investing more uncertain than the FDA clinical timeline alone would suggest.
CMS Policy
Breakthrough Devices
Reimbursement
Industry Shift
Story 03
Boston Scientific reported first-quarter 2026 results on April 22 that beat consensus estimates on both earnings and revenue. Adjusted EPS of $0.80 topped the $0.78 consensus. Net sales of $5.2 billion rose 11.6% year-over-year, with the cardiovascular segment surging 13.5% to $3.5 billion — driven by the FARAPULSE pulsed field ablation platform — and MedSurg growing 7.8% to $1.7 billion. The company guided for full-year 2026 organic sales growth of 7.0–8.5% with adjusted EPS of $3.34–$3.41. BSX has grown its ablation franchise at a pace that has outpaced even the company’s own earlier guidance since FARAPULSE received FDA clearance.
Why It Matters: The Q1 beat confirms that the pulsed field ablation inflection is structural, not cyclical. Hospitals are converting existing thermal ablation volume to PFA, and every converted case runs on FARAPULSE consumables. The RAPID pathway announcement is also directly favorable for BSX, which holds more breakthrough device designations than most competitors — and whose pipeline of next-generation structural heart and rhythm management devices now faces a meaningfully shorter path from approval to billable revenue.
Earnings Beat
PFA / Ablation
Full-Year Guidance
Story 04
Edwards Lifesciences reported first-quarter 2026 results on April 23 that beat consensus estimates and drove a sharp post-earnings surge in share price. Revenue rose 16.7% year-over-year to $1.65 billion. TAVR (transcatheter aortic valve replacement) revenue grew 14.4% to $1.2 billion. Adjusted EPS of $0.78 beat the $0.73 consensus. Edwards raised its full-year 2026 outlook, guiding for 9–11% sales growth (up from 8–10%) and adjusted EPS of $2.95–$3.05, citing durable procedure volume growth, expanding operator adoption in community heart centers, and early contribution from next-generation valve platforms.
Why It Matters: The TAVR market was supposed to be maturing. The 14% growth figure reflects two dynamics running in parallel: geographic expansion into under-penetrated markets where open surgery remains the default, and demographic inevitability as aging populations present with calcific aortic stenosis at rising rates. TMTT’s acceleration is a separate and equally important signal: if Edwards can replicate in the mitral and tricuspid segments what it did in aortic, the addressable market roughly triples from here.
Earnings Beat
TAVR / TMTT
Raised Outlook
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $516.20 | ▼ 0.4% |
| SYK | Stryker | $347.60 | ▲ 0.5% |
| JNJ | Johnson & Johnson | $246.80 | ▲ 1.5% |
| BDX | BD (Becton Dickinson) | $158.40 | ▼ 0.3% |
| ABT | Abbott | $99.10 | ▲ 0.5% |
| ZBH | Zimmer Biomet | $92.30 | ▼ 0.2% |
| MDT | Medtronic | $89.70 | ▲ 1.4% |
| EW ★ | Edwards Lifesciences | $86.90 | ▲ 6.2% |
| GEHC | GE HealthCare | $75.80 | ▲ 0.7% |
| BSX | Boston Scientific | $68.40 | ▲ 4.0% |
★ Biggest Mover: EW surged 6.2% after Edwards Lifesciences beat Q1 2026 estimates and raised its full-year outlook, driven by 14% TAVR growth and accelerating TMTT revenue. BSX rose 4.0% on its own Q1 beat and strong FARAPULSE pulsed field ablation results. JNJ gained 1.5% on the Atraverse Medical acquisition and positive read-through from the FDA/CMS RAPID pathway announcement. MDT added 1.4% on RAPID pathway favorability across its breakthrough device portfolio. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of April 22–26, 2026. For illustrative purposes only.
Deep Dive
The RAPID Pathway: Why 60 Days Changes the MedTech Business Model
The FDA and CMS RAPID Coverage Pathway is, on its surface, a process improvement. In practice, it is a structural shift in the risk profile of building and funding medical devices. To understand why, it helps to understand what the old system cost.
Under the pre-RAPID regime, a company winning FDA approval for a breakthrough-designated device faced a predictable second gauntlet. CMS would begin its own coverage determination process, which typically ran 9–12 months from approval — sometimes substantially longer. During that window, the device was technically legal to sell in the United States, but most hospitals would not purchase it because Medicare would not pay for the procedure. The commercial launch was effectively frozen. The company bore the full cost of that frozen period: sales infrastructure deployed and unproductive, clinical support teams standing by, manufacturing ramped but not shipping at scale.
The financial and strategic consequences cascade in several directions:
- Venture returns compress. The reimbursement gap consumed the post-approval commercial window that investors were counting on. A company with a 10-year patent runway effectively lost one to two years of commercial exclusivity to regulatory administrative delay.
- Hospital adoption stalls. The value analysis committee process at most health systems does not begin until reimbursement is confirmed. Even physician champions could not drive adoption inside an institution where the CFO would not authorize a technology without a payer coverage code attached.
- Small company risk compounds. For breakthrough-designation startups without the balance sheet to absorb 12 months of post-approval burn, the reimbursement gap was a known but unpredictable liquidity risk. Some companies that cleared FDA never reached commercial scale because the reimbursement delay outlasted their runway.
The RAPID pathway addresses all three. By making CMS coverage concurrent with FDA approval rather than sequential to it, the commercial launch clock starts the same day the approval letter arrives. Hospitals can begin their value analysis processes immediately. Investors can model commercial ramp without a blacked-out uncertainty window.
The companies best positioned to capture the RAPID pathway’s value immediately are those with large portfolios of approved breakthrough devices already in the field — Medtronic, J&J, and Boston Scientific. For the next wave of startups now in pivotal trials with breakthrough designation, the RAPID pathway should flow directly into investor models and commercial launch plans. The 9–12 month reimbursement risk buffer that founders and VCs have historically baked into projections can now be replaced with a 60–90 day assumption. That changes valuations, runway math, and hiring timelines. The pathway is administrative, but the downstream effects are capital.
The Builder’s Take
J&J Paid for 3,000 Procedures and Got the Entire Left Atrium. Every MedTech Founder Should Study Why.
The Atraverse acquisition looks small. Financial terms weren’t disclosed. The HOTWIRE system had been used in roughly 3,000 clinical procedures — meaningful traction, but not a franchise. What J&J actually bought was procedural position. Transseptal access is the gateway to every left-sided cardiac ablation, every mitral valve intervention, every left atrial appendage closure. It is the first step in the Biosense Webster workflow, before the CARTO mapping system fires up, before the catheter enters the field. By owning that first step, J&J now controls the on-ramp to a procedural ecosystem that already dominates EP labs globally. For founders building devices in medtech, this is the lesson: the companies acquiring right now aren’t chasing the biggest standalone revenue opportunities — they’re chasing devices that control procedural sequence. If your technology is the first thing that touches the patient in a high-value procedure owned by a platform player, your strategic value vastly exceeds your revenue. Build the on-ramp to someone else’s ecosystem, and the acquisition math writes itself.
Fun Fact
💡 Fun Fact — The Physics Behind the World’s Fastest-Growing Ablation Platform
Pulsed field ablation (PFA) — the technology behind Boston Scientific’s FARAPULSE system — works by a mechanism called irreversible electroporation. Instead of heating tissue (radiofrequency ablation) or freezing it (cryoablation), PFA delivers ultrashort electrical pulses — each lasting just microseconds — that create permanent nanoscale pores in cell membranes. The pores are large enough to disrupt the cell’s electrochemical balance, triggering apoptosis within hours. The key advantage is tissue selectivity: cardiac muscle cells are significantly more susceptible to electroporation than neighboring structures like nerves, blood vessels, and the esophagus. This means PFA can ablate atrial fibrillation circuits without the collateral damage risks — phrenic nerve palsy, esophageal injury, pulmonary vein stenosis — that have shadowed thermal ablation for two decades. The concept of electroporation was first described in the 1970s, but it took until 2023 for the first cardiac PFA system — FARAPULSE — to receive FDA approval in the United States, and the technology is now the fastest-growing ablation platform in the world.
Trivia
MedTech Trivia
Transcatheter aortic valve replacement (TAVR) received its first FDA approval in 2011 for inoperable high-risk surgical patients, based on results from the PARTNER trial. What was the primary clinical finding from the PARTNER trial that made TAVR a landmark result in interventional cardiology, and which institutions led the pivotal study?
👇 Scroll to the footer for the answer
MedTech Word Search
🧩 Find the Hidden MedTech Terms — Click to Highlight
FARAPULSE
ATRAVERSE
BIOSENSE
ABLATION
HOTWIRE
EDWARDS
CARDIAC
BOSTON
RAPID
TAVR
Words hidden in all 8 directions (→↓↘↗ and reverses). Click any letter in a word to reveal the full word.
Quick Question
The RAPID pathway covers roughly 40 breakthrough devices right now — but the real question is adoption velocity. Will hospitals actually move faster on value analysis, or will internal procurement timelines simply fill the gap that CMS just compressed? Where do you think the new bottleneck lands? Hit reply — I read every response.
Sponsor
